32,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
  • Broschiertes Buch

This book presents a compilation of articles from 2009 to 2017 on the characterisation of influenza A virus proteins as drug targets. It exemplifies the strategy of combining evolutionary biological and chemical information to predict drug target sites on influenza virus proteins that are unlikely to lead to drug resistance. In addition, computational virtual screening is applied to predict potential replication inhibitors of the polymerase basic protein 2. The reader is informed about strategies to deduce protein sequence conservation from highly redundant sequences and how to combine…mehr

Produktbeschreibung
This book presents a compilation of articles from 2009 to 2017 on the characterisation of influenza A virus proteins as drug targets. It exemplifies the strategy of combining evolutionary biological and chemical information to predict drug target sites on influenza virus proteins that are unlikely to lead to drug resistance. In addition, computational virtual screening is applied to predict potential replication inhibitors of the polymerase basic protein 2. The reader is informed about strategies to deduce protein sequence conservation from highly redundant sequences and how to combine sequence conservation with drug binding site prediction. This book is a useful resource for researchers in academia and industry starting out on drug discovery projects against pathogens with high sequence variability such as RNA viruses.
Autorenporträt
The author Andreas Kukol is a senior academic staff at the School of Life and Medical Sciences, University of Hertfordshire, UK. His research interests are centred on topics of structural and physical biochemistry including the properties of viral proteins and transmembrane protein-protein interactions that control cardiac function.